Tiziana Life Sciences is trading 5.6% higher at $0.94, with broader biotech strength (up 2.61% pre-market) providing the clearest immediate explanation. - Shares closed at $0.89 on September 22, 2026. - No company announcement was listed for September 23. - The latest major update was completion of the final patient visit in the 48-patient Phase 2a INFORM-MS trial; topline data is expected in October.